Cheek pouch (transbuccal) pharmaceutical composition

FIELD: pharmaceutical industry.

SUBSTANCE: pharmaceutical composition exhibiting neotropical, antiepileptic, sedative, and antistress activities, normalizing metabolic processes in body, contains aminoacetic acid and pharmaceutically acceptable carrier constituted by mixture of sorbitol and crosslinked carboxymethylcellulose sodium salt at weight ratio between 1:1 and 1:3 with additive selected from vinylpyrrolidone/vinyl acetate, stearic acid, stearic acid sodium salt, and mixtures thereof.

EFFECT: increased bioavailability and active component release velocity.

2 cl, 1 tbl

 

The invention relates to medicine, specifically to hominids (transbukkalnye) pharmaceutical compositions comprising aminouksusnoy acid (glycine)with nootropic, anti-epileptic, anti-stress, sedative, and normalizes metabolic processes in the body by the action.

Glycine is used in pharmacology in stress conditions, emotional stress, high anxiety, emotional lability, nervousness, neurosis-like States, dystonia, the consequences of neuroinfections and traumatic brain injury, various forms of encephalopathy, including alcoholic dysfunction, sleep disorders, to improve mental health, including adolescents with deviant behaviours in acute ischemic stroke (Register of medicines of Russia. Encyclopedia of drugs. Annual collection. 10 release. 2003 Moscow. Publishing house “radar-2003”, str).

Known drug anti-stress, stress-protective, nootropic action of sublingual application, comprising the amino acid glycine or its pharmaceutically acceptable salt and a pharmaceutical carrier, described in the patent of the Russian Federation No. 2025124. In the same document describes a method for the prevention and treatment of stress conditions by sublinguales introducing an effective amount of FA is pharmaceutical drug, containing glycine, and how to improve mental performance.

Famous drug is characterized in that it contains the active ingredient glycine in an amount of 0.1-0.2 g per tablet, as a pharmaceutical carrier preferably contains methylcellulose in an amount of 0.5 to 2 wt.%.

In the patent of Russian Federation №2082398 described a method of treatment of the acute period of ischemic stroke using glycine entered during the first five days of illness sublingual tablets to 1.0 g once a day.

In the patent of Russian Federation №2171673 described pharmaceutical composition for the manufacture of tablets and prolonged action, in particular sublingual application, and how you can get it. The pharmaceutical composition contains 98,1-and 99.8 wt.% not agglomerated particles of drug substance, coated with a polymer shell microcapsules), including 97,6-99 wt.% drug and 1-2,4 wt.% film-forming, 0.1 to 1.0 wt.% lubricating and 0.1 to 0.9 wt.% water. In the song entered the Ripper, representing the medicinal substance in an amount of 0.1-10 wt.% by weight of the mixture. As a medicinal substance can be used aminouksusnoy acid. As the lubricating component can be used stearic acid, its pharmaceutically acceptable salt, or a mixture thereof. As plantours the nes apply soluble in water or in an organic solvent or a mixture of the cellulose ethers. Raspadaemost this dosage form is at least 10 and no more than 30 minutes.

However, because raspadaemost sublingual tablets glycine in the case of sublingual (from Latin sub under, lingua - language) application method is up to 30 minutes, this is not always convenient and sometimes even undesirable, especially for children and the elderly. As you know, children are mostly not differ needed patience and can swallow the sublingual tablet before it resorption, which certainly complicates the action of a medicinal product intended for sublingual(sublingual) administration.

In addition, the elderly and children have weak swallowing ability, and therefore under-tongue (sublingual) method of application known drug for them is also difficult. The same argument can be given for the use of sublingual application method paralyzed patients.

Thus, it is important to establish a drug dosage form containing glycine as an active ingredient, having a much shorter time for complete dissolution in the oral cavity of the patient, and therefore more convenient and fast.

The problem is solved by the creation of a cheek or the so-called transbukkalno applications Leka is the only drug containing aminouksusnoy acid (glycine) or its pharmaceutically acceptable salt as the active substance. (According to the “List of names dosage forms used for registration of medicinal products”, approved by the Ministry of health of Russia, there are no 27.7 tablets cheek, No. 27.8 sublingual tablets.)

The new drug has a higher rate of dissolution in the oral cavity of the patient. This technical result is achieved by the fact that the claimed preparation containing as an active substance glycine and pharmaceutically acceptable carriers, and optionally contains sorbitol and Primerose (sodium salt of cross-linked carboxymethylcellulose (croscarmellose) mass ratio of from 1:1 to 1:3.

As pharmaceutically acceptability holders can also be used variants of a copolymer of vinylpyrrolidone with vinyl acetate, stearic acid and its salts, preferably calcium and magnesium, and mixtures thereof.

To improve the organoleptic properties of the pharmaceutical composition is proposed to introduce a composition pharmaceutically suitable excipients, for example, sweeteners and flavorings. As a sweetener can be used, for example, aspartame - N - L - alpha-aspartyl - L - phenylalanine - 1 - methyl ether. As flavourings can is to be used pharmaceutically suitable flavorings, for example, lemon and menthol.

The way to obtain a new composition includes a mixture of powders of glycine and pharmaceutical carriers with an aqueous solution of a copolymer of vinylpyrrolidone with vinyl acetate, wet granulation, drying, dry granulation and dusting. To give a composition of the form of tablets obtained after dusting composition is pressed on a tablet machine.

Obtained in this way the finished dosage form has a high raspadaemost 2-3,5 minutes, taste and meets the requirements of the State Pharmacopoeia XI.

The invention is illustrated by the following examples (table 1).



Table 1
IngredientsThe content of ingredients, wt.%
 123
Glycine93,593,5293,5
Kollidon VA 642-2
Polyplasdone 630-2-
Sorbitol crystalline0,641,330,88
Primerose2,021,331,78
Stearic acid -0,95-
Magnesium stearate0,97--
Calcium stearate--0,97
Aspartame0,15--
The lemon flavor0,720,87-
The total number of100100100
Raspadaemost, min
 23,53
Note: kollidon VA 64 and polyplasdone 630 - brand water-soluble copolymer of vinylpyrrolidone with vinyl acetate.

1. Pharmaceutical composition having nootropic, anti-epileptic, sedative, anti-stress, normalizes metabolic processes in the body effect, for hominids (transbukkalnye) form of the drug containing an effective amount aminouksusnoy acid or its pharmaceutically acceptability of salt as the active ingredient and the pharmaceutical carrier consisting of a mixture of sorbitol and sodium salt of cross-linked carboxymethyl cellulose in a weight ratio of from 1:1 to 1:3 in combination with an additive selected from the group comprising copolymers vinylpyrrole is it with vinyl acetate, stearic acid, a salt of stearic acid or mixtures thereof.

2. The pharmaceutical composition according to claim 1, characterized in that it contains aminouksusnoy acid or its pharmaceutically acceptable salt in an amount of 0.25 to 1 g in a single tablet.



 

Same patents:

FIELD: pharmaceutical chemistry, medicine.

SUBSTANCE: invention relates to new compounds of formula I ,

solvates or pharmaceutically acceptable salts having antiarrhythmic activity, including ventrical fibrillation, as well as pharmaceutical compositions containing the same. Compounds of present invention are useful in treatment or prevention of arrhythmia, modulation of ion channel activity, for topic or local anesthesia, etc. In formula I X is direct bond, -C(R6,R14)-Y- and C(R13)=CH-; Y is direct bond, O, S, and C1-C4-alkylene; R13 is hydrogen, C1-C6-alkyl, C3-C8-cycloalkyl, unsubstituted aryl or benzyl; R1 and R2 are independently C3-C8-alkoxyalkyl, C1-C8-hydroxyalkyl and C7-C12-aralkyl; or R1 and R2 together with nitrogen atom directly attached thereto form ring of formula II ,

wherein said ring is formed by nitrogen and 3-9 ring atoms selected independently from carbon, sulfur, nitrogen and oxygen, etc; R3 and R4 are independently attached to cyclohexane ring in 3-, 4-, 5-, or 6-position and represent independently hydrogen, hydroxyl, C1-C6-alkyl and C1-C6-alkoxy; and when R3 and R4 are bound with the same atom of cyclohexane ring they may form together 5- or 6-membered spiroheterocycle ring containing one or two heteroatoms selected from oxygen and sulfur; A is C5-C12-alkyl, C3-C13-carbocyclic ring, or ring structure as defined herein.

EFFECT: new antiarrhythmic drugs.

30 cl, 12 dwg, 34 ex

FIELD: medicine.

SUBSTANCE: preparation is a crushed and UV-radiation activated β-(3-indolyl)-α-aminocapronic acid obtained by treating dry initial preparation (native aminocapronic acid) crushed to 1-5 mcm large particles with UV-radiation during 12-18 h to the moment the substance decomposition starts. Method involves crushing dry substance of β-(3-indolyl)-α-aminocapronic acid by means of vibration mill with 1500-3000 oscillations per min to 1-5 mcm large particles, activating the crushed product by exposing it to UV-radiation of 250-280 nm wavelength during 12-18 h to the moment the initial substance decomposition starts. The moment is determined by 3-5% large initial mass loss.

EFFECT: enhanced effectiveness of the preparation with no adverse side effects.

6 cl, 3 tbl

FIELD: medicine, neurology, traumatology, neurosurgery.

SUBSTANCE: the present innovation deals with treating acute craniocerebral traumas (CCT). Since the first hours of therapy it is necessary to perform intravenous drop injection of 2-ethyl-6-methyl-3-hydroxypyridine succinate per 200 mg twice daily in case of severe degree of disease and per 200 mg once daily in case of average and light degrees of the trauma. The method provides detoxication effect in acute period of CCT due to recently established antitoxic action of the preparation suggested , that is accelerated degradation and withdrawal of toxic metabolites out of cerebrospinal liquid.

EFFECT: higher efficiency of therapy.

3 ex, 3 tbl

FIELD: pharmaceutics.

SUBSTANCE: the present innovation deals with peroral liquid compositions which could be designed into gelatinous capsules. The suggested pharmaceutical composition includes a pharmaceutically active agent, a solubilizing agent and, not obligatory, a surface-active substance and a plastifying agent. The pharmaceutically active agent has got, at least, one acidic fragment, preferrably, that of carbonic acid being chosen out of the group of non steroid antiphlogistic preparations being acid-soluble at acid : dissolved substance ratio being from 3:1 to 10000:1. New compositions provide increased rates and degrees of absorption of pharmaceutically active agent and minimize side effects caused by such active substances.

EFFECT: higher efficiency of application.

42 cl, 39 ex

FIELD: organic chemistry, pharmaceutical compositions.

SUBSTANCE: invention relates to substituted 3-oxo-1,2,3,4-tetrahydroxinoxalines of general formula 1 , wherein R1 represents substituted sulfanyl or substituted sulfonyl group, containing as substituent optionally substituted C1-C4-alkyl, optionally substituted C3-C8-cycloalkyl, aryl-(C1-C4)alkyl optionally substituted in aril or alkyl group, heterocyclyl-(C1-C4)alkyl optionally substituted in heterocycle or alkyl group; R2 and R3 independently represent hydrogen, halogen, CN, NO2, optionally substituted hydroxyl, optionally substituted amino group, optionally substituted carboxylic group, optionally substituted carbamoyl group, optionally substituted arylcarbonyl group or optionally substituted heterocyclylcarbonyl group; R4 and R5 independently represent hydrogen or inert substituent. Claimed compounds are high effective kaspase-3 inhibitors and are useful in production of pharmaceutical compositions for treatment of diseases associated with excess apoptosis activation, as well as for experimental investigations of apoptosis in vivo and in vitro. Also disclosed are pharmaceutical composition in form of tablets, capsules or injections in pharmaceutically acceptable package, as well as method for production thereof and therapy method.

EFFECT: pharmaceutical composition for apoptosis treatment and investigation.

6 cl, 3 dwg, 8 ex, 1 tbl

FIELD: pharmaceutical chemistry, medicine.

SUBSTANCE: in the suggested composition one should apply heptapeptide of Met-Glu-His-Phe-Pro-Gly-Pro sequence (heptapeptide A) for treating ischemic insult due to introducing 2 drops of compositions into each nasal canal 5-6 times daily for 10 d at disease of average severity degree, and in case of severe degree - per 3 drops of the present composition into each nasal canal 7 times daily for 10 d. The present innovation provides increased efficiency at decreased concentration of heptapeptide without any side effects.

EFFECT: higher efficiency of therapy.

2 cl, 6 dwg, 8 ex, 5 tbl

FIELD: medicine.

SUBSTANCE: the suggested preparation is being cytidine diphosphate choline (CDP-choline) known previously as the preparation to restore cerebral phospholipid structure and for treating mammalians, people among them, subjected to the action of stimulants. Moreover, it is necessary to note that CDP-choline decreases the duration of abstinence symptoms (tremor, convulsions, weakness, emotional instability, nervousness, social reserve) and causes either the decrease or stoppage of alcohol intake.

EFFECT: higher efficiency of therapy.

5 cl, 5 ex

FIELD: medicine, organic chemistry.

SUBSTANCE: the present innovation deals with new benzothiazole derivatives and medicinal preparation containing these derivatives for treating diseases mediated by adenosine receptor A2.A.. The present innovation provides efficient treatment of the above-mentioned diseases.

EFFECT: higher efficiency of therapy.

14 cl, 354 ex

FIELD: animal science.

SUBSTANCE: the suggested biopreparation named "Lactobifadol" should be applied 1 mo before the impact of the mentioned stress factor at the dosage of 100-200 mg/kg body weight, daily. Application of "Lactobifadol" enables to normalize physiological body state and decrease the losses of meat production.

EFFECT: higher efficiency of prophylaxis.

1 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: means comprises amber acid and/or its salts, fructose, dry extraction of Saint John's wort, magnesium ion sources, potassium ion sources as active bases and auxiliary substances, carriers and/or fillers when needed.

EFFECT: enhanced effectiveness of treatment.

4 cl, 4 tbl

FIELD: pharmaceutics, medicine.

SUBSTANCE: the present innovation deals with cardiotherapy for treating and preventing coronary deficiency. The preparation is designed as a plate (film) consisted of three layers, each of them is manufactured out of co-polymer of vinyl pyrrolidone, acrylamide and nitroglycerin-containing ethylacrylate; moreover, internal layer additionally contains solid fat - cacao oil, and weight ratio for the sum of external layers to internal corresponds to 1 : 1. The suggested preparation could additionally contain brilliant green dyestuff. The preparation should be manufactured out of pre-obtained mixture of nitroglycerin and copolymer in solution of alcohol and water followed by layer-by-layer forming three-layer film due to spreading the mixture onto solid bottom plate and drying at 30-50 C. The innovation provides higher adhesion to gingival mucosal surface, decreased side action, improved bioavailability and stability of therapeutic effect.

EFFECT: higher efficiency of therapy.

3 cl, 3 ex

FIELD: pharmaceutical industry, medicine.

SUBSTANCE: invention relates to peroral immediate-released drug in solid form, containing low molecular thrombin inhibitor based on peptide with pH-depending solubility. Claimed drug has size particle less than 300 mum and contains combination of microcrystal cellulose and sodium glycolate starch in amount of more than 35 mass % (calculates as preparation mass).

EFFECT: drug with reduced dependence of thrombin inhibitor dissolution from pH and increased releasing rate from tablet.

17 cl, 3 ex, 3 dwg

FIELD: medicinal industry.

SUBSTANCE: the present innovation deals with manufacturing medicinal preparation containing drotaverin hydrochloride to be applied for interrupting spasms of smooth musculature. Mass for tableting should be prepared due to mixing the powder of drotaverin hydrochloride with that of dyed granulate at the ratio of 1:3 to 2:1. One should obtain the dyed granulate by moisturizing inert pharmaceutical filler with binder's solution dyed with quinoline yellow dyestuff. Then comes drying up to 0.1-2.5% followed by granulation and tableting. The innovation enables to obtain tablets of drotaverin hydrochloride upon industrial equipment at its degradability being below 15 min, being stable during manufacturing and at storage. Quality of tablets meets all the requirements of pharmacopoeic article.

EFFECT: higher efficiency of manufacturing.

2 cl, 4 ex, 3 tbl

FIELD: medicine, hygiene.

SUBSTANCE: the present tablets are designed in solid form and contain the substance of purifying action in the form of finely dispersed insoluble abrasive components, SAS, aromatizing agents, dyestuffs, thickening agents, moreover, the content of water in components should be decreased by 35-37%. The suggested tablets should be prepared due to mixing the components with water to form solid forms out of obtained homogeneous plastic material at the room temperature to be then dried up and packed. Tablets for disposable intake provide great consumer's latitude being very convenient at usage.

EFFECT: higher efficiency of application.

16 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: the suggested composition includes therapeutically efficient quantity of para-aminosalicylic acid (PASA) as an active substance and target additives as sorbitol, polyvinyl pyrrolidone, salt of stearic acid, talc and citric acid. Pharmaceutical composition is designed as tablets covered with a membrane. The latter contains either "Acryl-iz" of Calarcon firm or composition consisting of copolymer of methacrylic acid with ethylacrylate, titanium dioxide, talc, propylene glycol and iron oxide. The suggested PASA-based antitubercular preparation meets all normative requirements of the State Pharmacopoeia, XI publication and has expiry terms of 2 yr.

EFFECT: higher efficiency of application.

6 cl, 3 ex, 1 tbl

FIELD: pharmaceutical industry.

SUBSTANCE: invention relates to porous quick-breaking active ingredient-containing granules based on chitosan or basic derivative thereof prepared by drop-by-drop technique, wherein aqueous solution or dispersion of chitosan or basic derivative thereof, one or several active substances, optional secondary active substances, and acid are dropwise added to cooling fluid at maximum temperature -5°C. As a result, solution or dispersion is solidified in the form of drops, which are then separated and dried. Such procedure is used to prepare therapeutical or diagnostic agents.

EFFECT: avoided use of gelatin or collagen as carrier.

16 cl

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical composition for oral administration in treatment or prophylaxis of obesity or hyperlipidemia. The composition comprises orlistat and at least one ester of fatty acids and polyols. Melting point of fatty acid ester exceeds the body temperature and polyol is taken among group including glycerol, sugars, derivatives of sugars and their mixtures. Also, invention relates to a method for preparing above described composition and to a method for treatment or prophylaxis of obesity. Invention enhances effectiveness and activity of orlistat by reducing variability of effectiveness and/or activity of orlistat between patients and frequency and severity of adverse effects.

EFFECT: improved and valuable pharmaceutical properties of compositions.

24 cl, 1 tbl, 10 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to nootropic, cerebroprotective medicinal agents as tablets. Tablet of a medicinal agent comprises thiotriazoline and piracetam as active components and accessory components used for formation of core and applying an envelope on it. Invention provides elevating rate and power of a medicinal agent effect on the brain blood supply, expanding spectrum of its pharmacological effect and excludes negative adverse effects.

EFFECT: improved and valuable medicinal properties of agent.

6 tbl

FIELD: pharmaceutical industry and technology, pharmacy.

SUBSTANCE: invention relates to a method for manufacturing a solid medicinal formulation - glucosamine hydrochloride tablets representing an anti-arthrosis preparation. Glucosamine hydrochloride, microcrystalline cellulose and average-molecular polyvinylpyrrolidone are placed in mixer followed by addition of talk and calcium stearate through a sieve in the process of stirring. Mixer is closed and stirring is continued and then mixture is tableted by the direct pressing method. Tablets are removed dust and dispensed. Invention provides making tablets by the improved technology wherein the labor-consuming granulation stage with using explosive reagent ethyl alcohol is excluded.

EFFECT: improved preparing method.

4 tbl, 3 dwg, 7 tbl

FIELD: pharmaceutical industry.

SUBSTANCE: invention provides antituberculous formulation made in the form of solid dosage form containing as active principle combination of isoniazid, rifampicin, pyrazinamide, ethambutol hydrochloride, and pyridoxine hydrochloride plus pharmaceutically acceptable auxiliaries: starch, lubricant, and optionally microcrystalline cellulose. Composition is characterized by storage stability and high therapeutical efficiency.

EFFECT: increased assortment of antituberculous drugs.

6 cl, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: method involves introducing oxybutinine solution into the urinary bladder via catheter in the amount of 5-10 mg per 20-30ml of sterile water once a day. Electrophoresis is concurrently carried out on the urinary bladder projection region using current intensity of 0.02-0.04 mA/cm2 during 15-20 min. The total treatment course is 10-12 daily procedures long.

EFFECT: enhanced effectiveness of treatment.

1 tbl

Up!